E
Nuvectis Pharma, Inc. NVCT
$9.49 $0.647.23%
Recommendation
Sell
Prev Close
$8.85
Volume
222,885
Avg Vol (90D)
147,391
Market Cap
$207.01M
Dividend & Yield
--
52-Week Range
$4.44 - $11.89
P/E (TTM)
--
EPS (TTM)
-$1.11
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Nuvectis Pharma initiated with a Buy at Laidlaw
3/17/2025 - TipRanks Financial Blog
Nuvectis Pharma initiated with bullish view at Laidlaw, here's why
3/17/2025 - The Fly
Nuvectis Pharma (NVCT, $8.85) RSI Indicator left the overbought zone on March 14, 2025
3/15/2025 - Tickeron - Stocks
Nuvectis Pharma to Participate in the 37th Annual Roth Conference
3/14/2025 - GuruFocus
Nuvectis Pharma to Participate in the 37th Annual Roth Conference
3/14/2025 - Globe Newswire
Nuvectis Pharma (NVCT, $7.62) entered Uptrend as Momentum indicator ascends above 0 level on Mar 10, 2025
3/11/2025 - Tickeron - Stocks
Nuvectis Pharma (NVCT, $7.62) entered Uptrend as Momentum indicator ascends above 0 level on Mar 10, 2025
3/11/2025 - Tickeron - Stocks
Market News Alert: Nuvectis Pharma's NXP900 Demonstrates Superior Efficacy in NSCLC When ...
3/5/2025 - GuruFocus
Market News Alert: Nuvectis Pharmas NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation
3/5/2025 - Business Wire
Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC
3/4/2025 - Globe Newswire
FY2028 EPS Forecast for Nuvectis Pharma Reduced by Analyst
2/28/2025 - MarketBeat
Nuvectis Pharma (NVCT, $6.71) entered Downtrend as Momentum indicator drops below 0 level on Feb 27, 2025
2/28/2025 - Tickeron - Stocks
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital ...
2/27/2025 - GuruFocus
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets
2/27/2025 - Business Wire
Nuvectis Pharma initiated with bullish view at Lucid Capital, here's why
2/26/2025 - The Fly
HC Wainwright Cuts Nuvectis Pharma (NASDAQ:NVCT) Price Target to $11.00
2/25/2025 - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Given New $11.00 Price Target at HC Wainwright
2/25/2025 - Ticker Report
Nuvectis Pharma price target lowered by $10 at H.C. Wainwright, here's why
2/25/2025 - The Fly
Nuvectis Pharma (NASDAQ:NVCT) Releases Earnings Results
2/25/2025 - Ticker Report
Nuvectis Pharma (NASDAQ:NVCT) Issues Earnings Results
2/25/2025 - MarketBeat
Nuvectis Pharma reports FY24 EPS ($1.11) vs. ($1.43) last year
2/25/2025 - The Fly
Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights
2/25/2025 - GuruFocus
Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights
2/25/2025 - Globe Newswire
Nuvectis Pharma (NVCT) to Release Earnings on Tuesday
2/25/2025 - MarketBeat
Nuvectis Pharma (NVCT, $7.52) RSI Indicator left the overbought zone on February 20, 2025
2/21/2025 - Tickeron - Technical Analysis
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$19.85M
Net Income (TTM)
-$19.00M
Balance Sheet
Total Assets (Q)
$18.61M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$8.89M
Book Value Per Share (Q)
$0.4982
Cash Flow
Cash from Operations (TTM)
-$12.25M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$11.65M
Net Change in Cash (TTM)
-$593.00K
Filings
Filing Date
Tuesday, February 25, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
0.94
7-Day Total Return
54.31%
30-Day Total Return
40.38%
60-Day Total Return
94.87%
90-Day Total Return
48.05%
Year to Date Total Return
76.07%
1-Year Total Return
-13.73%
2-Year Total Return
-13.41%
3-Year Total Return
23.73%
5-Year Total Return
--
52-week Low
Dec 20, 2024 - $4.44
52-week High
Mar 18, 2024 - $11.89
Valuation
Market Cap
$207.01M - Micro Cap
Enterprise Value
$188.48M
Price/Sales (TTM)
--
Price/Book (Q)
17.76
Dividends and Shares
Shares Outstanding
17.76M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.nuvectis.com
Phone Number
201 614 3150
Address
1 Bridge Plaza
Fort Lee, NJ 07024
Country
United States
Year Founded
2020
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. Its lead product... more
NASDAQ 03/17/2025 4:00PM Eastern Quotes delayed
Weiss Ratings